Abstract
The promotion of cellular survival, dedifferentiation, and uncontrolled proliferation via the suppression of apoptotic effectors is a fundamental characteristic of tumor cells. As substrates that are negatively regulated by oncogenic signaling cascades driven by AKT, SGK (serum- and glucocorticoid-inducible kinase), IkB kinase (IKK), ERK, and cyclin-dependent kinases (CDK), forkhead box-class O (FOXO) transcription factors have emerged as bona fide tumor suppressors. These transcription factors indeed regulate a variety of cellular responses and themselves are regulated by reversible phosphorylation, acetylation, ubiquitination and miRNAs. This review will discuss our current understanding of mechanisms for FOXO regulation and the potential implications for therapeutically restoring FOXO transcriptional activity.
Keywords: Apoptosis, FOXO, TRAIL, BIM, PP2A, proteasome, 14-3-3, micro RNA, PI3K, AKT, MIRNA, VELCADE, PS-341
Current Drug Targets
Title: Harnessing the Tumor Suppressor Function of FOXO as an Alternative Therapeutic Approach in Cancer
Volume: 12 Issue: 9
Author(s): Amrik Singh, Jessica Plati and Roya Khosravi-Far
Affiliation:
Keywords: Apoptosis, FOXO, TRAIL, BIM, PP2A, proteasome, 14-3-3, micro RNA, PI3K, AKT, MIRNA, VELCADE, PS-341
Abstract: The promotion of cellular survival, dedifferentiation, and uncontrolled proliferation via the suppression of apoptotic effectors is a fundamental characteristic of tumor cells. As substrates that are negatively regulated by oncogenic signaling cascades driven by AKT, SGK (serum- and glucocorticoid-inducible kinase), IkB kinase (IKK), ERK, and cyclin-dependent kinases (CDK), forkhead box-class O (FOXO) transcription factors have emerged as bona fide tumor suppressors. These transcription factors indeed regulate a variety of cellular responses and themselves are regulated by reversible phosphorylation, acetylation, ubiquitination and miRNAs. This review will discuss our current understanding of mechanisms for FOXO regulation and the potential implications for therapeutically restoring FOXO transcriptional activity.
Export Options
About this article
Cite this article as:
Singh Amrik, Plati Jessica and Khosravi-Far Roya, Harnessing the Tumor Suppressor Function of FOXO as an Alternative Therapeutic Approach in Cancer, Current Drug Targets 2011; 12 (9) . https://dx.doi.org/10.2174/138945011796150271
DOI https://dx.doi.org/10.2174/138945011796150271 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Detection of Predictive Markers for Therapeutic Stratification of Salivary Glands Tumors
Current Drug Targets Netrin and DCC: Axon Guidance Regulators at the Intersection of Nervous System Development and Cancer
Current Drug Targets Involvement of Cysteine Proteases in Cancer
Current Medicinal Chemistry Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Unmet Needs in Ovarian Cancer: Dividing Histologic Subtypes to Exploit Novel Targets and Pathways
Current Cancer Drug Targets Carotenoids as Modulators of Intracellular Signaling Pathways
Current Signal Transduction Therapy Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
Current Cancer Therapy Reviews Relevance of Aromatase Inhibitors in Breast Cancer Treatment
Current Topics in Medicinal Chemistry Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery A Review of Maternal and Fetal Growth Factors in Diabetic Pregnancy
Current Diabetes Reviews DNA Damage-inducing Compounds: Unraveling their Pleiotropic Effects Using High Throughput Sequencing
Current Medicinal Chemistry Targeted Radionuclide Therapy - An Overview
Current Radiopharmaceuticals SERMs: Evolutionary Chemistry, Revolutionary Biology
Current Pharmaceutical Design Aromatase Inhibitors: A New Reality for the Adjuvant Endocrine Treatment of Early-Stage Breast Cancer in Postmenopausal Women
Mini-Reviews in Medicinal Chemistry Site-related Effects of Relaxin in the Gastrointestinal Tract Through Nitric Oxide Signalling: An Updated Report
Current Protein & Peptide Science Mechanisms of Drug Resistance in Cancer Chemotherapy: Coordinated Role and Regulation of Efflux Transporters and Metabolizing Enzymes
Current Pharmaceutical Design Properties of the Mesenchymal Endometriotic Stem Cell in the Context of the Immune System and Analysis of its Role in Endometriosis
Recent Patents on Regenerative Medicine The Preclinical Bases of the Rational Combination of Paclitaxel and Antiangiogenic Drugs
Clinical Cancer Drugs The Influence of Salinomycin on the Expression Profile of mRNAs Encoding Selected Caspases and MiRNAs Regulating their Expression in Endometrial Cancer Cell Line
Current Pharmaceutical Biotechnology Signal Transduction Inhibitors in the Treatment of Breast Cancer
Current Medicinal Chemistry - Anti-Cancer Agents